Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.

Original publication




Journal article


Nature communications

Publication Date





MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.


Vero Cells, Animals, Humans, SARS Virus, Peptidyl-Dipeptidase A, Immunoglobulin A, Immunoglobulin A, Secretory, Immunoglobulin G, Antibodies, Monoclonal, Epitopes, Cross Reactions, Protein Binding, Mutation, Models, Molecular, Protein Interaction Domains and Motifs, Antibodies, Neutralizing, HEK293 Cells, Spike Glycoprotein, Coronavirus, Betacoronavirus, Chlorocebus aethiops, Angiotensin-Converting Enzyme 2, SARS-CoV-2